Literature DB >> 29951800

Hypertension: history and development of established and novel treatments.

Milan Wolf1, Sebastian Ewen1, Felix Mahfoud1, Michael Böhm2.   

Abstract

BACKGROUND: This article summarizes the emerging field of hypertension over the last decades. It covers paradigm shifts on hypertension from an undefined cardiovascular condition to the most relevant cardiovascular modifiable risk factor and the developments of drug treatments and interventional treatments to improve cardiovascular outcomes.
METHODS: We performed a selective literature research in PubMed on trials published in the past until 2018 without time restrictions and covered unpublished trials disclosed in ClinicalTrials.org.
RESULTS: The development of treatments of hypertension is a success story covering many decades from the early attempts with drug treatments, development of tolerable and effective medications to interventional techniques involving renal denervation, AV fistulas, and autonomic devices. Novel guidelines define new definitions and treatment targets of hypertension, which are a matter of ongoing discussion.
CONCLUSION: Despite the development of tolerable and effective drugs, new treatments in the field of neuroendocrine modulation by drugs and devices are still under development trying to further improve treatment of patients with hypertension and to further reduce cardiovascular events in those individuals.

Entities:  

Keywords:  Guideline overview; History of hypertension; Hypertension; Interventional treatment; Medical treatment

Mesh:

Substances:

Year:  2018        PMID: 29951800     DOI: 10.1007/s00392-018-1299-y

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  95 in total

1.  Total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy for hypertension.

Authors:  K S GRIMSON; E S ORGAIN; B ANDERSON; G J D'ANGELO
Journal:  Ann Surg       Date:  1953-10       Impact factor: 12.969

2.  THE EFFECT OF RENAL DENERVATION ON PATIENTS SUFFERING FROM NEPHRITIS.

Authors:  I H Page; G J Heuer
Journal:  J Clin Invest       Date:  1935-07       Impact factor: 14.808

3.  Pyrogens in the treatment of malignant hypertension.

Authors:  I H PAGE; R D TAYLOR
Journal:  Mod Concepts Cardiovasc Dis       Date:  1949-10

4.  Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design.

Authors:  Felix Mahfoud; Michael Böhm; Michel Azizi; Atul Pathak; Isabelle Durand Zaleski; Sebastian Ewen; Kostantinos Tsioufis; Bert Andersson; Peter J Blankestijn; Michel Burnier; Gilles Chatellier; Sameer Gafoor; Guido Grassi; Michael Joner; Sverre E Kjeldsen; Thomas Felix Lüscher; Melvin D Lobo; Chaim Lotan; Gianfranco Parati; Josep Redon; Luis Ruilope; Isabella Sudano; Christian Ukena; Evert van Leeuwen; Massimo Volpe; Stephan Windecker; Adam Witkowski; William Wijns; Thomas Zeller; Roland E Schmieder
Journal:  Eur Heart J       Date:  2015-05-18       Impact factor: 29.983

5.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

Review 6.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 10.190

7.  Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment).

Authors:  Eduardo M Krieger; Luciano F Drager; Dante M A Giorgi; Alexandre C Pereira; José Augusto Soares Barreto-Filho; Armando R Nogueira; José Geraldo Mill; Paulo A Lotufo; Celso Amodeo; Marcelo C Batista; Luiz C Bodanese; Antônio C C Carvalho; Iran Castro; Hilton Chaves; Eduardo A S Costa; Gilson S Feitosa; Roberto J S Franco; Flávio D Fuchs; Armênio C Guimarães; Paulo C Jardim; Carlos A Machado; Maria E Magalhães; Décio Mion; Raimundo M Nascimento; Fernando Nobre; Antônio C Nóbrega; Antônio L P Ribeiro; Carlos R Rodrigues-Sobrinho; Antônio F Sanjuliani; Maria do Carmo B Teixeira; Jose E Krieger
Journal:  Hypertension       Date:  2018-02-20       Impact factor: 10.190

8.  Renal denervation in hypertensive patients not on blood pressure lowering drugs.

Authors:  Rosa L De Jager; Margreet F Sanders; Michiel L Bots; Melvin D Lobo; Sebastian Ewen; Martine M A Beeftink; Michael Böhm; Joost Daemen; Oliver Dörr; Dagmara Hering; Felix Mahfoud; Holger Nef; Christian Ott; Manish Saxena; Roland E Schmieder; Markus P Schlaich; Wilko Spiering; Pim A L Tonino; Willemien L Verloop; Eva E Vink; Evert-Jan Vonken; Michiel Voskuil; Stephen G Worthley; Peter J Blankestijn
Journal:  Clin Res Cardiol       Date:  2016-04-22       Impact factor: 5.460

9.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321

View more
  5 in total

1.  Non-invasive evaluation of retinal vascular remodeling and hypertrophy in humans: intricate effect of ageing, blood pressure and glycaemia.

Authors:  Antonio Gallo; Thomas Dietenbeck; Alain Giron; Michel Paques; Nadjia Kachenoura; Xavier Girerd
Journal:  Clin Res Cardiol       Date:  2020-06-03       Impact factor: 5.460

Review 2.  Renal Denervation: Is It Ready for Prime Time?

Authors:  Lucas Lauder; Milan A Wolf; Sean S Scholz; Mathias Hohl; Felix Mahfoud; Michael Böhm
Journal:  Curr Cardiol Rep       Date:  2019-07-05       Impact factor: 2.931

3.  Cardiac-specific overexpression of metallothionein attenuates L-NAME-induced myocardial contractile anomalies and apoptosis.

Authors:  Lifang Yang; Jipeng Ma; Ying Tan; Qijun Zheng; Maolong Dong; Wei Guo; Lize Xiong; Jian Yang; Jun Ren
Journal:  J Cell Mol Med       Date:  2019-05-18       Impact factor: 5.310

4.  Determinants of hypertension treatment adherence among a Chinese population using the therapeutic adherence scale for hypertensive patients.

Authors:  Jingjing Pan; Lian Wu; Huichuan Wang; Tao Lei; Bin Hu; Xiaorong Xue; Qiongge Li
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

5.  Systematic review of renal denervation for the management of cardiac arrhythmias.

Authors:  Nakulan Nantha Kumar; Kuda Nyatsuro; Shiraz Ahmad; Ibrahim T Fazmin; Khalil Saadeh; Gary Tse; Kamalan Jeevaratnam
Journal:  Clin Res Cardiol       Date:  2021-11-08       Impact factor: 6.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.